MedTrace Logo

Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer

NCT05795296 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-08-30

No results posted yet for this study

Summary

The goal of this clinical trial is to explore the efficacy and safety in patients with gastric adenocarcinoma or adenocarcinoma of esophagogastric junction. The main questions it aims to answer are:

* Does this therapy have a promising efficacy?
* Does this therapy have a manageable toxicity? Participants will receive fruquintinib plus sintilimab as first-line therapy for gastric cancer.

Conditions

  • Stomach Neoplasms

Interventions

DRUG

Fruquintinib

Fruquintinib: 5mg po, d1-d14, q3w

DRUG

Sintilimab

Sintilimab: 200mg ivgtt, d1, q3w

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Shuiping Tu · RenJi Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2024-08-31
Completion
2025-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05795296 on ClinicalTrials.gov